Related references
Note: Only part of the references are listed.A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer
Ahmad Nasimian et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2023)
A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia
Alisa Damnernsawad et al.
HAEMATOLOGICA (2022)
AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
Marie-Anne Goyette et al.
CANCERS (2022)
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
Mari Iida et al.
BMC CANCER (2022)
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031
Jessica A. Pollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
Yuichi Murakami et al.
SCIENTIFIC REPORTS (2022)
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Anna Adam-Artigues et al.
SCIENCE ADVANCES (2022)
Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux
Rachael Nicholson et al.
FRONTIERS IN ONCOLOGY (2022)
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Daniel Bottomly et al.
CANCER CELL (2022)
Novel insights on [1,2]oxazolo[5,4-e]isoindoles on multidrug resistant acute myeloid leukemia cell line
Manuela Labbozzetta et al.
DRUG DEVELOPMENT RESEARCH (2022)
Overview of Human HtrA Family Proteases and Their Distinctive Physiological Roles and Unique Involvement in Diseases, Especially Cancer and Pregnancy Complications
Yao Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance
Zhijie Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia
Kinjal Shah et al.
NPJ PRECISION ONCOLOGY (2021)
Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD+ acute myeloid leukemia cells
Yi Liu et al.
ONCOLOGY LETTERS (2021)
The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
Martha Wium et al.
CANCERS (2021)
NTNG1 Modulates Cisplatin Resistance in Epithelial Ovarian Cancer Cells via the GAS6/AXL/Akt Pathway
Shanyu Fang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Machine learning in the prediction of cancer therapy
Raihan Rafique et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
KEGG: integrating viruses and cellular organisms
Minoru Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2021)
The great escape: tumour cell plasticity in resistance to targeted therapy
Soufiane Boumahdi et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
Phase 1 study of combinatorial sorafenib,G-CSF, and plerixafor treatment in relapsed/refractory,FLT3-ITD-mutated acute myelogenous leukemia patients
Gautam Borthakur et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia
Yue Zhong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
Claudia Cardone et al.
EUROPEAN JOURNAL OF CANCER (2020)
Mechanisms of Anticancer Therapy Resistance: The Role of Cancer Stem Cells
Julhash U. Kazi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Tyrosine Kinase Receptors in Oncology
Jorge Esteban-Villarrubia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736
Andrew S. Moore et al.
BLOOD ADVANCES (2020)
From local explanations to global understanding with explainable AI for trees
Scott M. Lundberg et al.
NATURE MACHINE INTELLIGENCE (2020)
Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
Pierre-Yves Dumas et al.
HAEMATOLOGICA (2019)
The role of SRC family kinases in FLT3 signaling
Julhash U. Kazi et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2019)
Roles of Cyclic AMP Response Element Binding Activation in the ERK1/2 and p38 MAPK Signalling Pathway in Central Nervous System, Cardiovascular System, Osteoclast Differentiation and Mucin and Cytokine Production
Yasuhiko Koga et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation
Rohit A. Chougule et al.
NPJ GENOMIC MEDICINE (2019)
FMS-LIKE TYROSINE KINASE 3/FLT3: FROM BASIC SCIENCE TO CLINICAL IMPLICATIONS
Julhash U. Kazi et al.
PHYSIOLOGICAL REVIEWS (2019)
HtrA4 Protease Promotes Chemotherapeutic-Dependent Cancer Cell Death
Tomasz Wenta et al.
CELLS (2019)
Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells
Mayu Takami et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia
Haitao Wang et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data
Steven Xijin Ge et al.
BMC BIOINFORMATICS (2018)
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
SCANPY: large-scale single-cell gene expression data analysis
F. Alexander Wolf et al.
GENOME BIOLOGY (2018)
Rare cell variability and drug- induced reprogramming as a mode of cancer drug resistance
Sydney M. Shaffer et al.
NATURE (2017)
Pathview Web: user friendly pathway visualization and data integration
Weijun Luo et al.
NUCLEIC ACIDS RESEARCH (2017)
Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
Jian-Zhong Lin et al.
ONCOTARGET (2017)
Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells
Chia-Herng Yue et al.
MOLECULAR MEDICINE REPORTS (2016)
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
O. Lindblad et al.
ONCOGENE (2016)
Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target
Andre Steven et al.
ONCOTARGET (2016)
FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia
Rohit A. Chougule et al.
ONCOTARGET (2016)
The Receptor Tyrosine Kinase AXL in Cancer Progression
Erinn B. Rankin et al.
CANCERS (2016)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Michael Juchum et al.
DRUG RESISTANCE UPDATES (2015)
Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells
Young-Ah Suh et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
Reversal of Cisplatin Resistance by Epigallocatechin Gallate Is Mediated by Downregulation of Axl and Tyro 3 Expression in Human Lung Cancer Cells
Kyung-Chan Kim et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
Il-Kyoo Park et al.
BLOOD (2013)
Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia
Julhash U. Kazi et al.
MEDICAL ONCOLOGY (2013)
Selective mutation in ATP-binding site reduces affinity of drug to the kinase: a possible mechanism of chemo-resistance
Nuzhat N. Kabir et al.
MEDICAL ONCOLOGY (2013)
FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL)
Nuzhat N. Kabir et al.
MEDICAL ONCOLOGY (2013)
Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3
De-Chen Lin et al.
BLOOD (2012)
Suppressor of Cytokine Signaling 6 (SOCS6) Negatively Regulates Flt3 Signal Transduction through Direct Binding to Phosphorylated Tyrosines 591 and 919 of Flt3
Julhash U. Kazi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
FLT3 and NPM1 Mutations in Myelodysplastic Syndromes Frequency and Potential Value for Predicting Progression to Acute Myeloid Leukemia
Ashish Bains et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations
Sebastian Scholl et al.
ANNALS OF HEMATOLOGY (2011)
Protein-tyrosine Phosphatase DEP-1 Controls Receptor Tyrosine Kinase FLT3 Signaling
Deepika Arora et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
A. S. Moore et al.
LEUKEMIA (2010)
Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
Chih-Chen Hong et al.
CANCER LETTERS (2008)
Activating FLT3 mutations are detectable in chronic and blast phases of chronic myeloproliferative disorders other than chronic myeloid leukemia
Pei Lin et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Share Paper
